Diagnostic Performance of Stool-based Testing for Colorectal Lesions Among Average-risk Individuals: A Real-world Evidence Study.

Autor:	Cheney C; Department of Medicine, Duke University Medical Center., Parish A; Department of Biostatistics and Bioinformatics, School of Medicine, Duke University, Durham, NC., Niedzwiecki D; Department of Biostatistics and Bioinformatics, School of Medicine, Duke University, Durham, NC., Oko C; Department of Medicine, Duke University Medical Center., Walters C; Department of Medicine, Duke University Medical Center., Sullivan BA; Department of Medicine, Duke University Medical Center.
Jazyk:	angličtina
Zdroj:	Journal of clinical gastroenterology [J Clin Gastroenterol] 2024 Aug 01. Date of Electronic Publication: 2024 Aug 01.
DOI:	10.1097/MCG.0000000000002053
Abstrakt:	Objective: We assessed the real-world performance of stool-based tests (SBTs) for colorectal cancer screening. Materials and Methods: Retrospective review of average-risk individuals with positive SBT for advanced neoplasia (adenocarcinoma, advanced adenoma, and/or advanced serrated lesions) detection at follow-up colonoscopy. Results: There was no statistical difference in the detection of advanced neoplasia (P= 0.16) between SBTs [30.7% for multitargeted stool DNA (mt-sDNA) vs 22.8% for fecal immunochemical test]. However, there was a significant difference in the detection of advanced serrated lesions (11.3% for mt-sDNA vs 1.8% for fecal immunochemical test, P< 0.001). Conclusion: There was no difference between SBTs for advanced neoplasia detection, though mt-sDNA detected significantly more advanced serrated lesions. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu